Kezar Life Sciences (KZR) is a clinical-stage biotech in active wind-down, with a signed Merger Agreement with Aurinia Pharma U.S. (executed March 30, 2026; tender offer commenced April 13, 2026 at $6.955/share cash plus one CVR). The liquidation lens is therefore not purely hypothetical — the company is functionally executing an orderly disposition of assets, and the balance sheet as of March 31, 2026 reflects that reality. Total assets are dominated by $66.2 million in cash and cash equivalents held entirely in U.S. Treasury money market funds (Level 1 fair value), which at a 100% recovery haircut constitutes the entirety of recoverable asset value. Property and equipment was fully disposed of in Q1 2026 as a result of restructuring ($3.5M gross cost fully written off; net book value zero at period end, down from $166K at December 31, 2025). No intangibles, no inventory, no debt. The operating lease was terminated on April 1, 2026 (a subsequent event) for a one-time payment of approximately $2.0 million, extinguishing the $1.4M operating lease liability carried on the March 31, 2026 balance sheet. Accrued liabilities totaled $1.1 million at March 31, 2026, down from $3.7 million at December 31, 2025, driven by substantial drawdown of accrued severance ($1.6M to $0.2M) and R&D accruals ($1.7M to near zero). Remaining accrued professional fees of $850K represent merger-related legal costs. Accumulated deficit stands at $496.3 million. Under the liquidation lens, net recovery to equity approximates cash ($66.2M) less all current liabilities ($1.1M accrued liabilities + $1.4M lease liability = $2.5M), yielding approximately $63.7M gross liquidation value. This is broadly consistent with MFFAIS's reported CLV/LLV/OLV of $65.3M, the slight difference attributable to the April 1, 2026 lease termination payment ($2.0M cash out post-period) and ongoing G&A burn. Post-merger close net cash condition of at least $50.0 million is a closing condition per the Merger Agreement, adding a contractual floor that constrains further cash dissipation. Unrecognized stock-based compensation of $2.6M will accelerate on executive separations per post-period Separation Agreements but is non-cash and does not affect recovery. Filing discusses executive separation agreements and CVR structure in MD&A but does not separately tag the associated contingent liability exposure in XBRL. The Onyx License Agreement carries up to $167.5M in contingent milestone obligations; none are currently probable and none are reflected in liabilities. No debt on balance sheet as of period end following October 2025 payoff of Oxford Finance facility.
▼ Community Notes